With the ability to reduce dysregulation secondary to COVID-19 autoimmunization, as noted by sustaining Nrf-2 levels and more balanced TH1/TH2, this combination therapy may also be utilized to reduce associated autoimmune and immunization sequelae such as myocarditis. This evidence concerns the gene NFE2L2 and COVID-19.